Recent Updates
Recently added Catalysts
ENGN Positive Sentiment

enGene to Host KOL Webinar on October 15, 2026

Tuesday, October 13, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: enGene Therapeutics Inc. has announced a webinar scheduled for October 15, 2026, at 10:00 AM ET. The session will delve into preclinical data regarding the use of its surfactant bladder rinse combined with detalimogene voraplasmid. This development targets patients who are unresponsive to Bacillus Calmette-Guérin (BCG) treatment.

Market Sentiment Analysis

POSITIVE FACTORS

  • enGene is advancing its genetic medicine approach.
  • The upcoming webinar aims to share significant preclinical data.
  • Focus on addressing high-risk BCG-unresponsive patients shows commitment.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~41 mo
Minimal dilution risk
Lead asset
EG-70
Phase 2 · Superficial Bladder Cancer

Full Press Release Details

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a webinar on Thursday, October 15, 2026 at 10:00 AM ET that will provide greater detail on the preclinical data supporting the incorporation of its surfactant bladder rinse plus detalimogene voraplasmid (detalimogene) into clinical development for Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk, no

Frequently Asked Questions

What is the date and time of the enGene webinar?

The enGene webinar is scheduled for October 15, 2026, at 10:00 AM ET.

What will be discussed in the enGene webinar?

The webinar will cover preclinical data on the surfactant bladder rinse and detalimogene.

Who is the target audience for the webinar?

The webinar targets stakeholders interested in BCG-unresponsive, high-risk patients.

What is detalimogene voraplasmid?

Detalimogene voraplasmid is a genetic medicine being developed by enGene.

ShareAdd on Google
Tags: ENGN enGene detalimogene BCG-unresponsive genetic medicines clinical development
Last updated: Oct 13, 2026

Biotech snapshot

Cash runway
$266M liquidity · $6M/mo burn
~41 mo
Minimal dilution risk
Lead asset
EG-70Phase 2
Superficial Bladder Cancer →